Phase I/II trial of intravesical methotrexate for superficial bladder tumors Journal Article


Authors: Sternberg, C. N.; Yagoda, A.; Bander, N. H.; Whitmore, W. F. Jr; Huffman, J. L.; Fleisher, M.; Melamed, M.; Fanucchi, M. P.; Hollander, P.; Vaughan, E. D. Jr
Article Title: Phase I/II trial of intravesical methotrexate for superficial bladder tumors
Abstract: Twenty-one patients with superficial transitional cell carcinoma of the bladder received a total of 121 doses of intravesical methotrexate (MTX) at 11 different concentrations of drug, ranging from 40 mg/m2 (mean concentration of 2.9×10-3M) to 500 mg/m2 (4.9×10-2M). Biochemical evidence of absorption was minimal in all cases. The maximum serum level was observed within 0.5-2 h in all patients and ranged from 1.8×10-8M to 5.0×10-7M. By 24 h the serum levels were negligible and ranged from 5.5×10-9M (the lowest limit detectable by the assay) to 4.4×10-8M in the patient who received the highest dosage of 500 mg/m2. Biologic evidence of absorption was minimal. Myelosuppression, mucositis, and nausea were not observed. Eighteen patients received six consecutive weekly doses ranging from 40 to 500 mg/m2. All patients had repeat cytoscopy performed within 2-4 weeks after six consecutive doses to evaluate local toxicity and efficacy. Flow cytometry was performed on the bladder washings of 22 patients, illustrating the use of flow cytometry, in conjunction with conventional cytology, as an additional means of objectively quantifying results. Despite MTX's established activity in systemic treatment of advanced bladder carcinoma, this study failed to demonstrate any clinical response to intravesically administered MTX, in doses of up to 500 mg/m2, and in concentrations of up to 4.9×10-2M. © 1986 Springer-Verlag.
Keywords: adult; cancer chemotherapy; clinical article; aged; aged, 80 and over; middle aged; unclassified drug; dose response; drug efficacy; methotrexate; flow cytometry; urinary bladder neoplasms; drug response; dna, neoplasm; urinary bladder; drug toxicity; cystoscopy; drug blood level; drug administration; carcinoma, transitional cell; bladder carcinoma; rna, neoplasm; adverse drug reaction; therapy; pharmacokinetics; cytodiagnosis; bladder; drug evaluation; intoxication; humans; human; male; female; priority journal; phosphorothioic triamide
Journal Title: Cancer Chemotherapy and Pharmacology
Volume: 18
Issue: 3
ISSN: 0344-5704
Publisher: Springer  
Date Published: 1986-12-01
Start Page: 265
End Page: 269
Language: English
DOI: 10.1007/bf00273400
PUBMED: 3802383
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 18 August 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Martin Fleisher
    312 Fleisher
  2. Willet F. Whitmore Jr
    139 Whitmore
  3. Myron Melamed
    148 Melamed
  4. Alan Yagoda
    51 Yagoda